4baseCare: Precision Oncology Startup Raises Rs 90 Crore

4baseCare, a leading precision oncology startup, has successfully secured Rs 90 crore (approximately $9.8 million) in the initial closing of its Series B funding round, which was co-led by Ashish Kacholia and Lashit Sanghvi, alongside participation from existing investor Yali Capital. This new funding comes after a two-year hiatus since their last investment round.

Utilising Fresh Capital for Expansion

In 2024, 4baseCare had raised $6 million in Series A funding led by Yali Capital, with backing from Infosys. The newly acquired funds will be pivotal in expanding 4baseCare’s network of hospital-linked genomics laboratories across regions including India, the Middle East, Southeast Asia, Latin America, and Central Asia. The investment will also aid in scaling its AI-driven precision oncology platform, OncoTwin, which enhances clinical decision-making for cancer treatments.

Focus on Clinico-Genomic Data

Founded by Hitesh Goswami, 4baseCare is dedicated to creating population-relevant clinico-genomic datasets to enhance cancer diagnosis and treatment outcomes, particularly within underserved populations. The OncoTwin platform effectively merges genomic testing with real-world clinical data, producing actionable insights for oncologists.

Recognition and Collaboration

The OncoTwin platform has been recently chosen for inclusion in the MSK iHub programme at the prestigious Memorial Sloan Kettering Cancer Center in New York. 4baseCare collaborates closely with hospitals to deliver genomics-led cancer diagnostics in clinical environments and is gearing up for expansion across emerging markets.

Growing Investor Interest in Cancer Startups

In recent years, investor interest in startups centred on cancer innovation has risen significantly. Last year, Everhope Oncology secured $10 million in seed funding, while MOC Cancer Care & Research Centre acquired $18 million led by Elevation Capital. Other funded startups in this sector include ErlySign, OnCare, and OneCell Diagnostics.